Efficacy and safety of switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from boosted protease inhibitor-based regimens in virologically suppressed adults with HIV-1: 48 week results of a randomised, open-label, multicentre, phase 3, non-inferiority trial
Titel:
Efficacy and safety of switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from boosted protease inhibitor-based regimens in virologically suppressed adults with HIV-1: 48 week results of a randomised, open-label, multicentre, phase 3, non-inferiority trial
Auteur:
Daar, Eric S DeJesus, Edwin Ruane, Peter Crofoot, Gordon Oguchi, Godson Creticos, Catherine Rockstroh, Jürgen K Molina, Jean-Michel Koenig, Ellen Liu, Ya-Pei Custodio, Joseph Andreatta, Kristen Graham, Hiba Cheng, Andrew Martin, Hal Quirk, Erin